Table 3.

In vitro potency comparison of MORAb-202 with farletuzumab conjugated with sulfo-SPDB-DM4

IC50 (nmol/L)
Cell lineFRA ExpressionMORAb-202Farletuzumab-sulfo SPDB-DM4EribulinDM4
IGROV1+++0.01 ± 0.000.09 ± 0.000.89 ± 0.042.56 ± 0.04
OVCAR3-A1+++0.06 ± 0.010.49 ± 0.010.15 ± 0.000.19 ± 0.01
NCI-H2110++2.20 ± 0.200.52 ± 0.010.27 ± 0.020.44 ± 0.01
NCI-N87+3.64 ± 0.470.82 ± 0.090.17 ± 0.020.69 ± 0.02
A431>1004.27 ± 0.861.05 ± 0.001.72 ± 0.06
  • NOTE: DAR of farletuzumab-sulfo-SPDB-DM4 was 3.5 (data not shown). IC50 values represent an average of three independent assays.